Guangdong Taienkang Pharmaceutical Co., Ltd.

XSEC:301263 Stock Report

Market Cap: CN¥6.3b

Guangdong Taienkang Pharmaceutical Past Earnings Performance

Past criteria checks 1/6

Guangdong Taienkang Pharmaceutical has been growing earnings at an average annual rate of 12.4%, while the Pharmaceuticals industry saw earnings growing at 9.1% annually. Revenues have been growing at an average rate of 7.4% per year. Guangdong Taienkang Pharmaceutical's return on equity is 6.6%, and it has net margins of 17.9%.

Key information

12.4%

Earnings growth rate

2.9%

EPS growth rate

Pharmaceuticals Industry Growth10.9%
Revenue growth rate7.4%
Return on equity6.6%
Net Margin17.9%
Next Earnings Update26 Apr 2025

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Guangdong Taienkang Pharmaceutical makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

XSEC:301263 Revenue, expenses and earnings (CNY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 2475213520775
30 Jun 2475113720571
31 Mar 2475615420664
31 Dec 2376116020663
30 Sep 2379118921264
30 Jun 2381420620957
31 Mar 2379417322450
01 Jan 2378317521540
30 Sep 2275916819429
30 Jun 2271214019025
31 Mar 2269715716425
01 Jan 2265412016626
30 Sep 2166112417731
30 Jun 2166812717432
31 Mar 2167013316532
31 Dec 2070916115731
30 Sep 2066213814833
30 Jun 2061211913330
31 Mar 205658713027
31 Dec 194965511724
30 Sep 194965610619
30 Jun 195126910520
31 Mar 19523769920
31 Dec 185147410020
30 Sep 18486719820
30 Jun 18480679720
31 Mar 18457588928
31 Dec 17450558924
30 Sep 17430438719
30 Jun 17408358614
31 Mar 1737831900
31 Dec 1636728900
30 Sep 1638238900
30 Jun 1639849900
31 Mar 1638445820
31 Dec 1537042750
30 Sep 1533736650
30 Jun 1530429560
31 Mar 1530535550
31 Dec 1430440520

Quality Earnings: 301263 has a high level of non-cash earnings.

Growing Profit Margin: 301263's current net profit margins (17.9%) are lower than last year (23.9%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: 301263's earnings have grown by 12.4% per year over the past 5 years.

Accelerating Growth: 301263's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: 301263 had negative earnings growth (-28.8%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (-2.5%).

Return on Equity

High ROE: 301263's Return on Equity (6.6%) is considered low.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/31 09:08
End of Day Share Price 2024/12/31 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Guangdong Taienkang Pharmaceutical Co., Ltd. is covered by 3 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Song YangTianfeng Securities Brokerage Co., Ltd
Tielin ChenTopsperity Securities
Xinming ZhouTopsperity Securities